Article
Basis of narrow-spectrum activity of fidaxomicin on gut pathogen <i>Clostridioides difficile</i>
2022-01-17
Abstract excerpt
Fidaxomicin (Fdx) is widely used to treat Clostridioides difficile ( Cdiff ) infections (CDIs), but the molecular basis of its narrow-spectrum activity in the human gut microbiome remains enigmatic. CDIs are a leading cause of nosocomial deaths. Fdx, which inhibits RNA polymerase (RNAP), targets Cdiff with minimal effects on gut commensals, reducing CDI recurrence. Here, we present the cryo-electron microscopy...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- e69e096f-d316-5a43-a885-a90ae396ba6a
- DOI
- 10.1101/2022.01.17.476619
